Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial)
I(b)期研究评估肿瘤内激动剂抗CD40(selicrelumab)联合抗PD-L1(atezolizumab)治疗难治性或复发性B细胞淋巴瘤患者的安全性和有效性(ITSELF试验)
期刊:ImmunoOncology and Technology
影响因子:
doi:10.1016/j.iotech.2025.101077
Alshatti, N; Lemonnier, F; Bachy, E; Lopez, J; Llamas, F; Damotte, D; Burron, B; Velut, Y; Mauduit, C; de Charette, M; Roussel, M; Palard, X; Marabelle, A; Huot, R
B细胞
肿瘤
T细胞
肿瘤免疫
淋巴瘤
CD40
PD-L1
细胞生物学
CD4
免疫/内分泌